RVMD Q1 2024 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$141M

Net Income

-$116M

EPS (Diluted)

$-0.70

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$161M

Free Cash Flow

-$164M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$183M

Stockholders' Equity

$1.7B

Cash & Equivalents

$288M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$7M	-100.0%
Gross Profit	$0	$7M	-100.0%
Operating Income	-$141M	-$75M	-87.4%
Net Income	-$116M	-$68M	-70.3%